Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shawn St. Peter, Children's Mercy Hospital Kansas City
ClinicalTrials.gov Identifier:
NCT00462020
First received: April 16, 2007
Last updated: December 12, 2011
Last verified: December 2011

April 16, 2007
December 12, 2011
March 2007
November 2008   (final data collection date for primary outcome measure)
Abscess After Appendectomy [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Abscess after appendectomy
Complete list of historical versions of study NCT00462020 on ClinicalTrials.gov Archive Site
Length of Stay, Charges, Adverse Events [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Length of stay, charges, adverse events
Not Provided
Not Provided
 
Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis
Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis

The objective of this study is to scientifically evaluate two different management strategies for perforated appendicitis.

The hypothesis is that early discharge with oral antibiotic therapy may result in a dramatic decrease in medical care expenses for the patient.

The primary outcome variable between the two strategies is abscess rate.

This will be a single institution, prospective, randomized clinical trial involving patients who present to the hospital with perforated appendicitis. This will be a definitive study.

Power calculation was based on abscess rate in the previous prospective, randomized study we just finished. Our current rate is 18%, or just under one-fifth of the patients. A doubling of this rate to 36% would place just over one third of the patients at risk which would be unacceptable. Using a delta of 0.18 with alpha of 0.05 and power of 0.8, the sample size is 74 patients in each arm. Therefore we will anticipate enrolling 150.

Subjects will be those children who undergo a laparoscopic appendectomy as part of their routine care.

Perforation will be defined as an identifiable hole in the appendix or stool in the abdomen.

The control group will receive current standard care: ceftriaxone 50mg/kg once a day (maximum dose = 2 grams) and metronidazole 30mg/kg once a day (maximum dose = 1 gram) with once a day dosing for both. The length of antibiotic therapy will be a minimum of 5 days. At that time, if they have been afebrile for at least 24 hours, a white blood cell (WBC) count will be obtained, and if that is within normal limits, the antibiotics will be discontinued and the patient will be discharged. If the WBC is elevated, they will receive another 2 days before recheck, if still elevated, they receive another 3 days and a CT is obtained. If, after 5 days of therapy, the patient remains febrile, therapy will continue until afebrile before a WBC check is performed. This is all our current standard management.

The experimental group will receive the same combination of antibiotics while in the hospital. When the patient is tolerating a regular diet, on oral pain medication and has been afebrile for over 12 hours, they will be discharged on oral antibiotics to complete a course of 7 days. The home antibiotic regimen will be ampicillin/clavulanic acid (Augmentin®). Augmentin® dose will be 40mg/kg twice a day. They will be asked to bring their pill containers with them to clinic where we will quantify medication compliance.

Given the purpose of this study is the comparison of oral antibiotics to intravenous antibiotics, an allergy to one of the above medications will not be considered an exclusion criteria. In such cases the patient will be treated with an alternative that offers the same spectrum of coverage, but will be included in the study.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Perforated Appendicitis
  • Drug: 5 days of IV antibiotics (ceftriaxone and metronidazole)
    5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
  • Drug: Home with oral antibiotics when eating (ampicillin/clavulanic acid)
    Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
  • Active Comparator: 1
    5 days of IV antibiotics after appendectomy
    Intervention: Drug: 5 days of IV antibiotics (ceftriaxone and metronidazole)
  • Experimental: 2
    home on oral antibiotics to complete 7 days of treatment when tolerating PO's
    Intervention: Drug: Home with oral antibiotics when eating (ampicillin/clavulanic acid)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
November 2008
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Identifiable hole in the appendix or stool in the abdomen at the time of appendectomy

Exclusion Criteria:

  • Known immune deficiency
  • Abscess identified on pre-op imaging
  • Another condition affecting surgical decision making or recovery (e.g. hemophilia, severe cardiac or respiratory co-morbidities).
Both
up to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00462020
07 02 031
No
Shawn St. Peter, Children's Mercy Hospital Kansas City
Children's Mercy Hospital Kansas City
Not Provided
Principal Investigator: Shawn D St. Peter Children's Mercy Hospital
Children's Mercy Hospital Kansas City
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP